Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossMedicare Advantage · Coverage · Medical Policy · Oncology, Endocrinology, Gastroenterology +2 moreMedium impact

MA08.090i, Lanreotide (Somatuline Depot)

Act
by Sep 4, 2026
Effective date
Sep 4, 2026
Identified
Sep 5, 2026

Summary

Independence Blue Cross updated MA08.090i to expand Lanreotide (Somatuline Depot) coverage to include four new condition categories: carcinoid syndrome, CNS sellar tumors, and neuroendocrine tumors of the GI tract/lung/thymus and pancreas, aligned with NCCN guidelines. Billing teams must verify patient diagnoses match the expanded criteria before claim submission to ensure coverage under HCPCS codes J1930 and J1932.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

by Sep 4, 2026 · 4 steps
01Billing team and clinical staff must update internal documentation and billing system notes to reflect expanded coverage criteria for Lanreotide (Somatuline Depot).
02Review patient records to identify newly eligible diagnoses (carcinoid syndrome, CNS sellar tumors, GEP-NETs, neuroendocrine tumors of GI tract/lung/thymus/pancreas).
03Update prior authorization templates and encounter forms to include the specific medical necessity criteria outlined in the policy.
04When submitting claims for J1930 or J1932, ensure diagnosis codes match one of the four newly covered condition categories and document that applicable clinical criteria are met.
If missed: Failure to align claims with updated coverage criteria may result in denials for previously non-covered indications.

Codes mentioned

J1930J1932

Original notice

MA08.090i, Lanreotide (Somatuline Depot)
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
08.01.40i, Lanreotide (Somatuline Depot)MediumEffective Sep 4, 2026 · Medical PolicyMA08.090h, Lanreotide (Somatuline® Depot)MediumEffective Nov 17, 2025 · Pharmacy08.01.40h, Lanreotide (Somatuline® Depot)MediumEffective Nov 17, 2025 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesOncologyEndocrinologyGastroenterologyNeurosurgeryPulmonologyCode J1930Code J1932

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account